AtonRa Partners Has $441,000 Stock Holdings in BioNTech SE (NASDAQ:BNTX)

AtonRa Partners trimmed its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 11.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 4,175 shares of the company’s stock after selling 532 shares during the period. AtonRa Partners’ holdings in BioNTech were worth $441,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. CWM LLC increased its holdings in shares of BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares during the period. Covestor Ltd acquired a new position in BioNTech in the 3rd quarter valued at approximately $32,000. UMB Bank n.a. acquired a new stake in shares of BioNTech during the 4th quarter valued at $50,000. Ramirez Asset Management Inc. purchased a new position in shares of BioNTech during the 3rd quarter valued at $76,000. Finally, PNC Financial Services Group Inc. increased its stake in shares of BioNTech by 42.4% in the third quarter. PNC Financial Services Group Inc. now owns 840 shares of the company’s stock worth $91,000 after acquiring an additional 250 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BNTX. HC Wainwright restated a “buy” rating and issued a $107.00 target price on shares of BioNTech in a research note on Wednesday, April 17th. UBS Group dropped their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. The Goldman Sachs Group cut their price objective on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 28th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. Finally, Oppenheimer began coverage on shares of BioNTech in a report on Friday, January 5th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $120.40.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $0.74 during trading hours on Monday, hitting $87.95. 409,157 shares of the stock were exchanged, compared to its average volume of 661,236. The firm has a market capitalization of $20.91 billion, a P/E ratio of 21.35 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. BioNTech SE has a one year low of $85.21 and a one year high of $125.83. The company’s 50 day moving average is $90.69 and its 200 day moving average is $96.18.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. On average, research analysts expect that BioNTech SE will post -1.73 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.